Table 1
Mean (±standard error) serum AST and ALT levels in the control, resveratrol, FB1, and FB1 +resveratrol groups receiving IP treatment for 14 days
Table 2
Mean (±standard error) liver TAS in the control, resveratrol, FB1, and FB1 +resveratrol groups receiving IP treatment for 14 days
Table 3
Mean (±standard error) liver TOS in the control, resveratrol, FB1, and FB1 +resveratrol groups receiving IP treatment for 14 days
Table 4
Mean (±standard error) serum TSA levels in the control, resveratrol, FB1 and FB1 +resveratrol groups receiving IP treatment for 14 days

Figure 1
Comparison of liver histologies between the study groups. (A) normal liver histology in a mouse from the control group; (B) severe hyperaemia (white arrows), inflammatory cell infiltrations (black arrow), and megalokaryosis (arrow head) in a mouse from the FB1 group; (C) normal liver histology in a mouse from the resveratrol group; (D) normal liver histology in a mouse from the FB1+resveratrol group. Scale bar=50 µm
